BICYCLE THERAPEUTICS PLC Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Bicycle Therapeutics Plc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2018 to Q3 2024.
  • Bicycle Therapeutics Plc Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $9.2M, a 23.8% increase year-over-year.
  • Bicycle Therapeutics Plc Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $35.6M, a 17.7% increase year-over-year.
  • Bicycle Therapeutics Plc annual Share-based Payment Arrangement, Expense for 2023 was $32.5M, a 21.3% increase from 2022.
  • Bicycle Therapeutics Plc annual Share-based Payment Arrangement, Expense for 2022 was $26.8M, a 122% increase from 2021.
  • Bicycle Therapeutics Plc annual Share-based Payment Arrangement, Expense for 2021 was $12.1M, a 85.5% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $35.6M $9.2M +$1.77M +23.8% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 $33.8M $9.26M +$1.07M +13.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $32.7M $9.28M +$240K +2.65% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $32.5M $7.81M +$2.27M +41% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-20
Q3 2023 $30.2M $7.43M +$2.06M +38.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 $28.1M $8.19M +$2.52M +44.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $25.6M $9.04M -$1.16M -11.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $26.8M $5.54M +$2.54M +84.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-20
Q3 2022 $24.2M $5.37M +$2.68M +99.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $21.6M $5.67M +$3.1M +120% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $18.5M $10.2M +$6.38M +167% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $12.1M $3M +$1.44M +91.8% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-20
Q3 2021 $10.6M $2.69M +$1.18M +78% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $9.47M $2.58M +$1.26M +95.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $8.21M $3.82M +$1.7M +80.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $6.51M $1.56M +$481K +44.4% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 $6.03M $1.51M +$691K +84.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $5.34M $1.32M +$414K +45.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $4.93M $2.12M +$1.85M +668% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $3.08M $1.08M Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $819K +$589K +256% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $905K +$570K +170% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $276K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q3 2018 $230K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $335K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.